These therapies, the first an antibody and the second of a class
called tyrosine kinase inhibitors (TKIs), reduce the ability of a target gene to manufacture the protein it encodes.
Drugs
called tyrosine kinase inhibitors (TKIs) are generally successful at controlling the cancer.
Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors
called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.
Not exact matches
In 2005, Cagan's team created a general fly model of a human thyroid tumor caused by mutations in the Ret receptor
tyrosine kinase gene, then screened a panel of drugs including a
kinase inhibitor called vandetanib that suppressed the tumor (Cancer Res, 65:3538 - 41, 2005).